Phio Pharmaceuticals Corp logo

Phio Pharmaceuticals Corp(PHIO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.77
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PHIO

11/13/2026: PHIO (1-star) is currently NOT-A-BUY. Pass it for now.

Phio Pharmaceuticals is an early-stage biotechnology company focused on developing proprietary self-delivering RNA interference (sd-RNAi) therapeutics for cancer. Its primary investment story centers on the potential of its INTASYL platform to revolutionize how immune cells are treated to fight tumors. While the technology offers a specialized approach to immuno-oncology, the company remains pre-revenue and highly dependent on external funding, which introduces significant financial and dilution risks. The stock best suits long-term, high-risk-tolerant investors interested in clinical-stage biotech developments. Key developments to monitor include upcoming clinical trial data for PH-762 and the company's ability to secure strategic industry partnerships.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company's early-stage, pre-revenue status presents extreme growth risks.
Momentum investorWeak fitThe stock often lacks the consistent volume or trend strength required for momentum strategies.
Value investorWeak fitThere is no earnings or cash flow base to provide a traditional valuation floor.
Dividend investorWeak fitThe company does not pay a dividend and requires cash for R&D.
Low-risk investorWeak fitHigh clinical and financial volatility make this unsuitable for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks in early-stage development often experience wide swings based on clinical data or financing news.
Valuation riskHighWithout revenue, valuation is highly speculative and subject to market sentiment.
Competition risk (Immuno-oncology competition)HighThe company faces competition from well-funded giants that can outspend it on clinical trials.
Business qualityMediumWhile the technology is proprietary, the business lacks commercial scale.
Dividend incomeLow / noneNo income is generated or distributed to shareholders.
Execution riskHighSuccessful drug development requires complex clinical and regulatory execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.21M USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 75.6K shares
Beta 0.92
52 Weeks Range 0.75 - 1.88
Updated Date 11/14/2026
52 Weeks Range 0.75 - 1.88
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.12

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -61.79%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PHIO receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
PHIO has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-21.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
PHIO's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
PHIO's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-21.7%, negative) and free-cash-flow growth (-12.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 10.2% (soft) and 94.2% of outstanding shares are publicly tradable (strong). Insider ownership of 8.01% supports management-shareholder alignment.

Top 5 Institutional Investors

Jane Street Group LLC 1.01%
Geode Capital Management, LLC 0.99%
Vanguard Capital Management, LLC 0.81%
Delaware Management Holdings Inc 0.43%
Cetera Investment Advisers 0.41%

Unit Economics (Per $1K Revenue)

★★★★★
PHIO generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
PHIO has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biotechnology R&DFocus on development of clinical-stage oncology drug candidates.The company is currently burning cash to research drugs and does not sell products.

Valuation

Trailing PE -
Forward PE 0.31
Enterprise Value -683.17K
Price to Sales(TTM) 48.01
Enterprise Value -683.17K
Price to Sales(TTM) 48.01
Enterprise Value to Revenue 172.2
Enterprise Value to EBITDA 0.61
Shares Outstanding 11.95M
Shares Floating 11.26M
Shares Outstanding 11.95M
Shares Floating 11.26M
Percent Insiders 8.01
Percent Institutions 10.2

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.